$TGGI Updated Milestones/Analysis/Achievements Below:

New Post Public Reply Private Reply Replies (1) Message Board
ResidualRevenue
583
$TGGI Updated Milestones/Analysis/Achievements Below:

Twitter: https://twitter.com/transggi @transggi
Facebook Group: https://www.facebook.com/groups/TGGIstockfanpage/


Those doubting $TGGI need to read the proof in the pudding. This will go boom and you will be left chasing if you don't get in.



Summary of Current/Pending Accomplishments

-Net Income $381,794.54 per 3rd Qtr Report (Confirmed)
-Already Eyeing Distribution Partners In Reno (In the works)
-Initial Funding for Cannabis Consortium to be in place in October 2017 with investors already lined up. (In The Works)
-TGGI owns 90% of Cannabis (Confirmed)
-TGGI will retain ownership of over 50% of Cannabis after Reg-A Filing (Confirmed - Pending Reg A)
-50% of Income of Cannabis goes to TGGI (Confirmed Upon Reg-A Completion)
-Massive Share Reduction On O/S. A/S. Float (Confirmed)
-2 BILLION Share Reduction of O/S/Float (In the works)
-TA Is Not Gagged (Confirmed)
-OTC Pink Current (Confirmed)
-No Debt of Any Kind (Confirmed)
-No Dilution (Confirmed)
-No Chance of R/S (Confirmed)
-Transparent CEO (Confirmed)
-4 Audited Revenue Streams Set Up (Confirmed upon Reg-A completion and distributions)
-Business in multiple states such as CO, FL, CA and DE (1/2 in the works 1/2 complete)
-CO Office Open in January 2018 (In the works)
-New FL Corporate OFfice Will Be Ready for Occupancy December 1st 2017 (In The Works)
-Licence deals (In the Works)
-Cocoa Industry (Confirmed)
-MJ Industry (Confirmed)
-MMJ industry for animals (In the Works)



$TGGI IS A NO BRAINER.

https://www.otcmarkets.com/financialReportVie...;id=180522 Click Here To View Q3 Report With Expanded Info on Cannabis Consortium

https://www.accesswire.com/viewarticle.aspx?id=477574 Click Here To View 10/11/2017 PR

Recent Twitter Updates:
DMnyi1kVoAAW0ZX.jpg

DL5NFIuVoAEJ_Z5.jpg

DL-OYslUQAEIAhK.jpg


Investor Posted Updates and Opinions:

Quote:
SilverShehz 10/11/2017 - Personal Analysis
Technically speaking, in 2009, during bear market TGGI gapped downwards and there is an unfilled void between .33 to .40 cents. You can check this on investing.com. Regardless of time (days, weeks, months or years) the market has to fill that void. With regards to price movements, elliot waves, gartley's gap theory, etc. this is inevitable. Check out the chart on investing.com and read about gap theory on investopedia.com. Those who bought this, be patient. Know that some are either shorting this or wanting this to correct lower so they can buy lower. They are not your well wishers that they are going to come here and specifically make you aware of some BS so that you don't buy. If you are still skeptical know that you are playing the otc market and company buy backs or share reduction seldom happens. This may be a golden opportunity so hold tight. If you wanna unload do so, but don't completely get rid of it. This is of course in my humble opinion.

Quote:
ImDerekD 10/9/2017 - Personal Analysis/Audit Breakdown
http://www.mediafire.com/view/xv3bm23g10h8s8b....15_PM.png Click Here

Above is just how I audit E/R's & "score" them. I made sure to include the significant events in the most recent filing just so nobody hypes/panics about a rumor. $CENX was a perfect example. Free-falled after meida reported bad EPS & revenue w/ out looking @ other basic accounting principles. But, regardless... yeah. Ya welcome


Quote:

StockInvestor01 10/6/2017
EMAIL REPLY FROM Matt/TGGI:

I emailed Matt to confirm whether Cannabis Consortium was a subsidiary or a spin-off.

His response: I will state this, you cannot spin off a company you do not own 100% of. I am not doing a back door R/S and no one absolutely no one has to swap their shares at all.

Since he confirmed that CC is a bonafide subsidiary, I replied and asked about the percentage TGGI owns of Cannabis Consortium and what percentage of CC revenues will show up on the TGGI balance sheet:

His response: That info will be in the forth coming report.



Quote:
EMAIL REPLY FROM MATT/TGGI THIS EVENING:
Received 9pm EST on 9/27/2017:

The release is very straight forward and breaks down the various points the company was seeking to make.

The Pr makes no reference to Cannabis becoming a share selling machine, if that is what I wanted to do I could have done that years ago I own 3 shells. I also did not have to return 530 million shares of my own stock that cost ME $56,250 to get, or cancel the debt I owned which I have the wire confirmations to prove the money was invested in the Company over years. How do you think any actions have been paid for the past 2 years? I still am owed money from the Company it is not convertible and it never will be.

I am not sure why everyone is acting the way they are, the Pr is full of very positive news and the plans will move forward. TGGI will benefit tremendously from this transaction.

Yes, Cannabis is filing a Reg A, what is the problem with that? Are companies now not allowed to use Reg A to raise capital? The financials will be audited moving forward is that a problem now?

The Company will be revenue generating sooner than anyone claims and I designed the company to be that way without and licensing needed. Why would a company create redundant expenses in multiple cities when it can very easily enter into very lucrative licensing deals with existing operations? The revenue streams from the licensing based on the pricing of a similar product (which I did make mention of) are very favorable.

The Company can ship to any market without violating any FEDERAL laws. The products have applications outside of the MJ market which means an even larger market.

I have delivered what I said I would regardless of how people wish to view the Pr. I did not build up expectations the Company could not deliver upon.

Maybe people should read the Pr again and read it without thinking of what they wanted to see and see what is there.

I am not changing my course of action or my direction for TGGI or Cannabis. Those who can see the forest through the trees will be rewarded those who can't will not.

Patents, molds, trademarks, licensing deals are all valuable assets to be owned and Cannabis will have multiple. I haven't even finished releasing all the parts of Cannabis and people are jumping off buildings.

Regards,

Matthew Dwyer
President
Trans Global Group, Inc.


Documented PR notes, Email Responses and Share Reductions:

DL31k5JXUAAECKQ.jpg

DL31k4zXkAUgr_X.jpg

DL31k4yWAAE0dJA.jpg

DL31k42W0AADmcc.jpg

DLc7e_HV4AAL7hd.jpg

DLc7e_NVoAAc5pY.jpg

DLU5k7tU8AEbfAJ.jpg

DLU5k7sUQAECvqw.jpg

DLFaViJUMAAvJ0J.jpg

DKMIGoaVYAEnt-R.jpg

DKLwsYUUIAMsvFl.jpg

DKGuJ7yUIAA6Nmy.jpg

DJxRTGhUEAAMQUF.jpg

DIj4XakUIAImVcJ.jpg
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Gildan's Crisis: Investors Face Losses Amid Lawsuit

Updated Category News Views 245

Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 308

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 337

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
GlycoNex Eyes Japanese Market with Denosumab Biosimilar

Updated Category News Views 9

A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...

Continue Reading
Antengene’s AnTenGager-D2 Advances in Cancer Treatment

Updated Category News Views 26

Antengene's AnTenGager-D2 Offers Fresh Hope Alright, let's dig into the latest buzz from the 2026 Society for Immunotherapy of Cancer conference about Antengene's AnTenGager-D2 platform. If you're not into biotech lingo, buckle up, because this is a ride into the future of cancer treatments—where science fiction might soon become science fact. A Novel Approach to Tumor...

Continue Reading
Fibocom LTE Modules Test Drive Satellite Connectivity

Updated Category News Views 153

Boosting IoT with Satellite Connectivity Here's a good one for folks watching the edge of wireless innovation. Fibocom's LTE Cat.1 bis modules, the LE270-EU and LE271-GL, just stretched their legs in New Zealand, connecting seamlessly with SpaceX's Direct to Cell (DTC) satellite system. No fancy hardware swaps, just standard firmware strutting its stuff across satellite...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 344

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 273

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
Innovent's SINTBILO® Hits Primary Endpoint in Study

Updated Category News Views 78

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Continue Reading
Cleaner Air in Bedroom May Stabilize Blood Sugar Levels

Updated Category News Views 321

Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...

Continue Reading

Top 5 Most Recently Viewed Articles

Stretch Zone Expands Horizons with Canadian Studio Launch

Updated Category News Views 214

Stretch Zone's Exciting New Chapter in Canada Stretch Zone, a trailblazer in the realm of assisted stretching, has embarked on a significant milestone by opening its first studio in Canada. This new location is not just a store but a powerful symbol of the brand's commitment to enhance flexibility and mobility in communities beyond the United States. The Vision Behind the...

Continue Reading
Eilean Therapeutics Unveils Groundbreaking JAK2 Inhibitor ZE74-0282

Updated Category News Views 585

New Frontiers in JAK2 Inhibition by Eilean Therapeutics Eilean Therapeutics LLC, a pioneering biotechnology company, is set to make waves in cancer treatment with its latest development, ZE74-0282, a wild-type-sparing JAK2-JH2/V617F inhibitor. The company has announced an exciting presentation at the upcoming American Society of Hematology (ASH) Annual Meeting, focusing...

Continue Reading
PodcastOne Extends LadyGang Contract as It Approaches 1000 Episodes

Updated Category News Views 116

PodcastOne Renews its Agreement with LadyGang Podcast PodcastOne, a key player in the podcasting world, is thrilled to announce the renewal of its contract with the immensely popular LadyGang podcast, hosted by Keltie Knight, Becca Tobin, and Jac Vanek. Launched in 2015 on PodcastOne, this engaging podcast has resonated with millions of listeners and is gearing up to...

Continue Reading
BCA Research Warns Upcoming Rate Cuts May Be Insufficient

Updated Category News Views 73

BCA Research Warns Rate Cuts May Arrive Too Late BCA Research has expressed concerns about the upcoming rate cuts, suggesting they might not effectively address a potential recession. The firm points out that the effects of monetary policy often lag, meaning the economy is still grappling with the repercussions of previous tightening measures. Market Sentiments and...

Continue Reading
SOMOS Pilates Nashville: A Vibrant Rebranding Journey

Updated Category News Views 235

SOMOS Pilates Nashville: A Vibrant Rebranding Journey In an inspiring shift, Studio Pilates Nashville has announced its rebranding as SOMOS Pilates Nashville. This transition marks a significant evolution, aimed at celebrating the studio's growth and commitment to community-centered movement practices. Welcoming a New Identity The rebranding initiative reveals more than...

Continue Reading